The Global Cell Dissociation Solution Market was valued at USD 430.15 Million in 2022 and is projected to reach USD 1100.20 Million by 2030, registering a CAGR of 15.55% for the forecast period 2023-2030.
A proteolytic enzyme helps break down proteins to release adhered cells from the cell culture vessel during the cell dissociation process, which is also referred to as trypsinization. So that the cells can be utilized again, this breakdown is required. In order to disengage the cell tissues, cell dissociation reagents can perform collagenolytic and proteolytic actions. The proliferation of cell-based research, which was started by numerous pharmaceutical and biotechnology companies, is the main factor driving the growth of the cell dissociation market. Furthermore, there are more and more of these biotech and pharmaceutical companies in the world. Thus, this is yet another element driving the market for cell dissociation. The biotechnology sector requires sophisticated tissue-dissociating enzymes. The market is expanding as a result of this demand. One major industry driver is the growing emphasis on the development of cell-based therapeutics. Cell-based therapeutics, sometimes referred to as cell therapies or regenerative medicine, use live cells to treat illnesses, heal injured tissues, and help patients' cells function normally again. One of the most important steps in growing cells for treatment is cell dissociation.
- 2022: USD 430.15 Million
- 2030: USD 1100.20 Million
- CAGR (2023-2030): 15.55%
Cell Dissociation Solution Market Dynamics
Drivers Propelling the Demand for Cell Dissociation Solution include:
Increasing demand of cell-based therapies will fuel the market expansion:
Cells are used in cell-based therapies to regenerate or repair damaged or diseased tissues or organs. Because they have the potential to treat a number of illnesses that are currently difficult or impossible to treat using conventional methods, these treatments have received a lot of attention recently. Because they have several advantages over traditional therapies such as fewer side effects, increased efficacy, and the potential for long-lasting effects cell-based therapies are becoming more and more popular. For example, stem cell therapy is being studied as a possible treatment for conditions like spinal cord injury, Parkinson's disease, and heart disease. Comparably, CAR T-cell therapy has shown promise in the management of certain malignancies, including lymphoma and leukemia. In order to make these medications, large quantities of specific cells are required. Cell dissociation solutions are essential tools for isolating and preparing these cells for use in different therapies. As a result, as the need for cell-based therapies increases, so does the demand for treatments that cause cell dissociation. The demand for cell-based therapies is rising as more people become aware of the possible advantages of these treatments. The demand is fueling the market for cell dissociation solutions by increasing investment in research and development related to cell-based therapy, thus all factor driving the growth of cell dissociation solution market.
For instance, in February 2022. According to Cell & Gene, Cell and gene therapies are one of the most active areas of research and investment in the development of medicine. The cell and gene therapy space are experiencing significant growth and attracting substantial investment due to its potential in targeting poorly treated diseases and the recent success of novel therapies.
Technologies in Cell Dissociation Products Drive Industry expansion:
The market for cell dissociation solutions is expected to grow as interest in regenerative and personalized medicine grows. Examining a patient's genetic profile to identify potential treatment options is a crucial step in the cell dissociation process. Cell-based therapeutics and regenerative medicine solutions are developed using cell dissociation materials. The need for cell dissociation products is anticipated to increase as infectious and chronic diseases spread more widely. Diabetes, Alzheimer's disease, and cancer can all be diagnosed and treated with the help of cell-based assays. The market's revenue is being driven by technological advancements in cell dissociation products. The use in research and development applications may rise with the development of reagents and kits that offer effective cell dissociation. Cell dissociation is becoming more efficient and repeatable thanks to automated dissociation platforms. Typically, these platforms combine robotic systems for handling and processing cells with enzyme or non-enzymatic dissociation methods. Automation technology developments are resulting in dissociation platforms that are easier to use and have greater versatility. Because every tissue has distinct properties, researchers are creating customized dissociation solutions for various tissue types. This customized strategy is reducing damage and maintaining cell integrity while facilitating a more effective and efficient dissociation of cells from diverse tissues, due to this factor, cell dissociation solution market is fueling.
For instance, in September 2022, according to Cellenion, SCIENION and its subsidiary Cellenion, both companies’ part of the bio convergence powerhouse BICO, announced the release of the proteoCHIP LF 48. This chip represents the first commercially available solution enabling reproducible automated miniaturized single- cell proteomics sample preparation and standardized workflow for label-free single-cell mass spectrometry-based proteomics analysis. The proteoCHIP LF 48 was developed in partnership with the Research Institute of Molecular Pathology in Vienna
- February 2021
Cytiva, a global life science leader, and the State of Telangana in India will work together to open a new Fast Trak lab. The city of Hyderabad in Telangana, which has emerged as a leader in pharmaceuticals and biotechnology, is well-positioned to host such a facility. The 10,000 square foot lab, to be located in the Genome Valley, will accelerate and advance the local biopharma scale up needs. With over 800 life sciences companies nearby, the new facility will help the area’s biotechnology hub increase production efficiency, reduce cost and speed to market.
- March 2023
Acquisition will make electron capture dissociation (ECD) technology available to more biopharma researchers and labs globally, Agilent Technologies Inc. announced the acquisition of e-MSion, an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell.
Restraint in the Cell Dissociation Solution Market
Cell Dissociation Solution's Exorbitant Cost is Limiting Market Growth:
The high cost of cell dissociation solutions is one of the main problems facing the industry. These goods are expensive due to a variety of factors. To begin with, the materials needed to prepare cell dissociation solutions can be costly. Many of these remedies include costly and difficult-to-find biological ingredients, such as enzymes. The cost of these materials may increase if they must be purchased from specialized suppliers or undergo complex production processes. Second, the procedure for making solutions for cell dissociation can be challenging and time-consuming. Common procedures in the production process include the extraction, purification, and formulation of enzymes. Because each of these stages requires specific equipment and expertise, the cost of production goes up. Expensive products are used in the isolation and purification of cell organelles, and automated or semi-automated benchtop instruments are more costly than conventional techniques. Even though automated instruments have many advantages, their high cost could prevent products from being widely adopted. Low profit margins and high production costs can deter manufacturers from creating novel and creative dissociation solutions. This may hinder market innovation and reduce the number of high-quality products available. In order to stay competitive, businesses may feel pressure to cut prices, but doing so can further erode profit margins and make it more difficult to fund R&D. For new businesses looking to enter the market, the high cost of creating and producing dissociation solutions may be a barrier. Innovation and competition may be hampered by this, overall, this factor hindered the growth of cell dissociation solution market.
For instance, in June 2021, according to pib.gov, Ministry of Science & Technology, The Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a breakthrough in cancer treatment. Clinical trials conducted globally have shown promising results in end stage patients, especially in patients suffering from Acute Lymphocytic Leukemia. Though this technology has a remarkable therapeutic potential for cancer patients, at present this technology is not available in India. Each patient's CAR-T cell therapy costs USD 3,65,853 to 4,87,804.
Challenges in the Cell Dissociation Solution Market
Restrictions related to divided cell culture.
Dissociated cultures have fewer cells than immortalized cell lines, which is their main drawback. As a result, carrying out biochemical experiments requiring a large volume of starting materials becomes challenging. Furthermore, the majority of primary cell cultures exhibit heterogeneity, presenting a formidable obstacle for cell dissociation experiments. It can be challenging to isolate a particular cell population in neural cultures because these cultures frequently contain mixtures of neurons and glia that react to various neurotransmitters. Centrifuges, laminar flow hoods, and other specialized equipment and facilities are needed for divided cell culture. The development of novel cell-based treatments and diagnostic tools may be hampered by the difficulty that researchers and physicians may have conducted divided cell culture experiments due to the scarcity of these resources. Continuous care of divided cell cultures is necessary, and this includes frequent feeding, observation, and cleaning. Researchers and medical professionals may find it challenging to carry out long-term studies or to scale up cell production for therapeutic applications due to the high cost of maintaining cell cultures.
Opportunities in the Cell Dissociation Solution Industry
Developments in tissue dissociation without enzymatic means
To get ahead of the competition and increase sales, market players are launching cutting-edge and novel products. For the purpose of separating cells from primary tissues, the majority of researchers in R&D centers and biotechnology businesses have traditionally depended on conventional enzymatic dissociation products. While there are benefits to using these conventional enzymatic dissociation products, like improved dissociation during research, they can also occasionally be cytotoxic and harm living cells. Many businesses are launching non-enzymatic, non-cytotoxic products to address this problem and set themselves apart from the competition. Because of this benefit, more and more end users are requesting non-enzymatic dissociation products. The cost of the enzymes used in enzymatic tissue dissociation techniques can make them costly. Since non-enzymatic techniques don't need enzymes, they may be more affordable. Researchers and physicians may find cell dissociation solutions more affordable as a result. When using enzymes derived from animals, such as those used in tissue dissociation, ethical questions may arise. Since non-enzymatic techniques don't need enzymes derived from animal sources, they can get around these moral dilemmas.
|Market Size in 2022
|USD 430.15 Billion
|Market Forecast in 2030
|USD 1100.20 Billion
|Compound Annual Growth Rate (CAGR)
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product, By Application, By End-User & By Region
|2018 - 2022
|2023 - 2030
Segment Analysis of the Cell Dissociation Solution Market
The cell dissociation solution market is segmented by product, application, end-user and region.
The Enzymatic Dissociation segment held the largest market share in 2022:
By product is sub segmented into enzymatic dissociation, non-enzymatic dissociation, instrument & accessories. The enzymatic dissociation segment accounted for highest market share 48% in global cell dissociation solution market for 2022. The breakdown of cell-to-cell and cell-to-substrate adhesions is greatly aided by enzymes. They are the go-to option for routine cell dissociation applications because of their ability to effectively separate cells from culture surfaces and tissues. Furthermore, enzymatic dissociation techniques are adaptable and suitable for a variety of cell types and tissue sources. Because of their adaptability, they can be used in a wide range of bioprocessing and research applications, such as stem cell culture and cancer cell isolation. They can also be expanded for use in large-scale cell culture and industrial bioprocessing. In order to create biologics and cell-based treatments, this scalability is necessary. The main factor influencing the dominance of enzymatic dissociation products is the collagenase segment. Although there are over 20 distinct kinds of collagenases, only a few are best suited for the tissue-enzyme dissociation process. The quantity of viable, dissociated cells can be maximized with these appropriate collagenases. When it comes to the dissociation of liver, epithelial, adrenal, and adipocyte tissue, collagenase type 1 is usually advised.
On the other hand, the non-enzymatic dissociation segment has the significant market share over the forecast period, due to functional and structural integrity of the cell surface proteins is preserved by the enzyme-free formulation. Avoiding the cytotoxic effects linked to chelating agents is an additional advantage. Furthermore, there is a growing regulatory scrutiny surrounding the use of components derived from animals in the production of biopharmaceuticals. Thus, in order to propel segment growth, non-enzymatic products for cell culture must be developed.
The tissue dissociation segment was the leading segment in 2022:
by application, which is divided into cell detachment, tissue dissociation. The tissue dissociation segment accounted for largest share 57% in global Cell Dissociation Solution market for 2022. Tissue dissociation techniques are adaptable and useful in many different fields of study. They are employed in drug discovery, regenerative medicine, immunology, neuroscience, and cell biology. Tissue dissociation techniques are often needed by researchers in order to isolate and examine particular cell populations within different tissues. Tissue dissociation techniques are used by the pharmaceutical industry to develop cell-based assays for drug testing and screening. Dissociating tissues speeds up the process of finding and developing new drugs by enabling researchers to examine how various medications interact with particular cell types and tissues. Tissue dissociation is also used to isolate cell populations for proteomic and genomic analyses, such as protein analysis, gene expression profiling, and DNA sequencing.
On the other hand, the bakery and confectionery segment is anticipated to expand over the forecast period, in order to cultivate adherent cells, cell detachment is essential. The most popular method of detachment is trypsinization. Increasing funding for the launch of novel products through cell culture and strategic initiatives by major industry players are two of the main factors propelling this segment's growth.
The Pharmaceutical & Biotechnology Companies segment was the leading segment in 2022:
By end-user, which is divided into pharmaceutical & biotechnology companies, research & academic institutes. The pharmaceutical & biotechnology companies segment accounted for largest share 72% in global Cell Dissociation Solution market in 2022. Companies in the pharmaceutical and biotechnology industries are leading the way in drug development. To screen possible drug candidates, investigate disease mechanisms, and assess the safety and efficacy of drugs, they mainly rely on cell dissociation techniques and models. Cell dissociation is also necessary for the isolation and preparation of therapeutic cells, such as immune or stem cells, as well as for growing cell lines, keeping bioreactors operating, and harvesting cells for biomanufacturing procedures. Additionally, the businesses use cell dissociation to separate patient-specific cells for study and the creation of new treatments, particularly in the context of rare and cancerous diseases. The dominance of this market segment has also been aided by these companies' increased R&D investments over the past few years.
Research & Academic Institutes segment is anticipated to register rapid growth in forecast period, Drug discovery, regenerative medicine, and cell biology are areas of intense academic and scientific research. Cell dissociation solutions are needed for these research activities in order to separate and purify cells from tissues. Therefore, the biggest users of cell dissociation solutions are research and academic institutions.
North America occupied the largest market share in 2022:
North America has the largest revenue market share 38% in 2022, The market is being driven by a multitude of pharmaceutical and biotechnology companies, in addition to favorable government initiatives. These businesses mainly rely on cell dissociation techniques for a range of purposes, such as cell-based therapies, drug screening, and biomanufacturing. Furthermore, biotech startups and well-established businesses in North America are leading the way in innovative research and promoting the use of sophisticated cell dissociation techniques. Furthermore, the markets in North America are renowned for embracing cutting-edge technologies and research instruments quickly. Businesses in the area are quick to adopt cutting-edge methods for cell dissociation that provide increased accuracy, efficiency, and cell viability.
On the other hand, Asia Pacific accounted for the significant share over the forecast period, The pharmaceutical markets in Asia-Pacific are still very fragmented and fiercely competitive, with thousands of small manufacturers vying for market share. Government support is anticipated to stimulate innovation in life sciences research and the expansion of the pharmaceutical and biopharmaceutical industries from an economic and policy perspective. Increasing government spending on research and development as well as quick infrastructure development are two more important factors driving the growth of the regional market. Furthermore, a number of local businesses are getting funding to research and develop treatments for a range of chronic illnesses, including cancer.
List of the prominent players in the Cell Dissociation Solution Market:
- Merck KGaA
- Thermo Fisher Scientific
- Danaher Corporation
- STEMCELL Technologies
- Sartorius AG
- Miltenyi Biotec
- HiMedia Laboratories
- F. Hoffmann-La Roche Ltd
- S2 Genomics, Inc.
Segmentation Analysis of the Cell Dissociation Solution Market
- Enzymatic Dissociation
- Non-Enzymatic Dissociation
- Instrument & Accessories
- Tissue Dissociation
- Cell Detachment
- Pharmaceutical & Biotechnology Companies
- Research & Academic Institutes
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Impact of the COVID-19 Pandemic on the Cell Dissociation Solution Market:
Due to the significant role that cell culture technologies have played in the discovery of novel therapeutic and diagnostic options for COVID-19, there has been an increase in demand for cell culture products. For example, culturing techniques provide valuable tools for producing viral particles for the development of vaccines, expanding the market's growth potential. The primary driver of the industry's expansion is the increased emphasis on creating cell-based treatments. Growth in the market is being driven by an increase in clinical trials, FDA approvals, and strategic initiatives by major players. COVID-19 pandemic has had a mild effect on the market and healthcare systems. The pandemic has presented vital opportunities for growth. Research and development efforts to analyze and assess the virus that started the pandemic have doubled. As a result, developed countries with a large number of research organizations will probably see faster market growth. Conversely, nations in the Asia-Pacific area and other developing regions have stepped up their studies of the novel coronavirus. On the other hand, the COVID-19 pandemic has significantly impacted hospital resources globally. It has mostly been achieved by implementing infection prevention and control techniques and sharply cutting back on inpatient and outpatient services for a variety of illnesses. The global pandemic has caused a sharp decline in the frequency of cancer screenings and diagnostic procedures.